Immuno-Oncology 360° Agenda 2026 Page 2

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Showing Events in 1 Track from 08:45am to 09:25am

State of the IO Market, Investments and Deals Plenary

8:45AM - 9:05AM

IO Capital Markets Outlook for Biotechs & IO

Lorenzo Paoletti, MBA, Managing Director, Biopharma Investment Banking, Bank of America

9:05AM - 9:25AM

M&A Strategies in Biotech: Navigating the Path to Acquisition

Rick Aldridge, MBChB, Managing Director, Healthcare Investment Banking

Showing Events in 1 Track from 09:25am to 10:05am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

9:25AM - 10:05AM

Morning Networking Break

Showing Events in 1 Track from 10:05am to 10:50am

IO360° Biotech Showcase

10:05AM - 10:50AM

IO360° Biotech Showcase

Participating Companies:

Showing Events in 1 Track from 10:50am to 10:55am

5 Minute Health Break

10:50AM - 10:55AM

5 Minute Health Break

Showing Events in 1 Track from 10:55am to 12:15pm

State of the IO Market, Investments and Deals Plenary (Continued)

10:55AM - 11:35AM

What Makes a Smart Deal in IO? Navigating Capital, Competition, and Global Innovation

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Markus Werner, PhD, Head, Search & Evaluation, Oncology, Novartis

Evan Zisholtz, JD, VP, Global Business Development, Immunai

11:35AM - 12:15PM

IO Investment Trends: What’s Driving Capital in 2026?

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Reni Benjamin, PhD, Managing Director, Citizens Capital Markets and Advisory

Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley

Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments

I-hung Shih, PhD, MBA, Managing Director & Portfolio Manager, Eventide Asset Management

Showing Events in 1 Track from 12:15pm to 01:15pm

Lunch

12:15PM - 1:15PM

Lunch & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 01:20pm to 03:20pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers

1:20PM - 1:40PM

VIP Talk: Targeting Myeloid Cells for Therapeutic Enhancement

Miriam Merad, MD, PhD, Chair, Department of Immunology and Immunotherapy, Director, Marc and Jennifer Lipschultz Precision Immunology Institute, Director, Mount Sinai Human Immune Monitoring Center, Mount Sinai School of Medicine

1:40PM - 2:00PM

Reserved for Natera

2:00PM - 2:20PM

Engineering the Optimal T Cell Engager: From Molecular Design to Clinical Translation

Julie Bailis, PhD, Associate Vice President, Acting Head of Oncology Research, Amgen

2:40PM - 3:00PM

Synergizing Cell Therapy with Oncolytic Viruses for Enhanced Tumor Targeting

Barbra Sasu, CSO, Dispatch Bio

3:00PM - 3:20PM

First-in-Human Imaging of a Zirconium-89-Labeled Monoclonal Antibody in Small Cell Lung Cancer

Diederik Grootendorst, PhD, Director, Global Oncology Imaging, Bristol Myers Squibb

TRACK 2: IO Cell Therapy Plenary

1:20PM - 1:55PM

In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment

Adrian Bot, MD, PhD, EVP, R&D and Founding CSO, Capstan Therapeutics

Jacek Lubelski, PhD, Chief Technology Officer, NanoCell Therapeutics

1:55PM - 2:15PM

Beyond T Cells: The Rise of Non-Immune Cell Therapies

2:15PM - 2:30PM

Islet Transplantation for Type 1 Diabetes

Fouad Kandeel, MD, PhD, Arthur D Riggs Distinguished Chair in Diabetes and Metabolism Research, Professor and Chair Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope

2:30PM - 2:45PM

Autologous iPSC Therapy for Parkinson’s

2:45PM - 3:20PM

iPSC 2.0: From Promise to Productization

Dhavalkumar Patel, MD, PhD, EVP & CSO, Sana Biotechnology

Gregory Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics

Bahram (Bob) Valamehr, PhD, President & CEO, Fate Therapeutics

Showing Events in 1 Track from 03:20pm to 04:00pm

Afternoon Networking Break

3:20PM - 4:00PM

Afternoon Networking Break & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 04:00pm to 05:30pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers

4:00PM - 5:30PM

Breakthroughs in Translational Science, Imaging & Biomarkers Sessions Coming Soon

TRACK 2: IO Cell Therapy Plenary

4:00PM - 4:35PM

Rebuilding TCR-T Cell Therapy: Novel Targets, Smarter Circuits, and the Road to Universality

Moderator:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Eric Tran, PhD, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute

Elizabeth Wood, PhD, CEO & Founder, Jura Bio, Inc

4:35PM - 5:10PM

Beyond the Bench: AI Integration Across the Cell Therapy Pipeline

5:10PM - 5:30PM

The State of TIL Therapy: Innovation, Lessons Learned, and What’s Next

Fireside Guests:

Micah Benson, PhD, CSO, KSQ

Showing Events in 1 Track from 05:35pm to 06:10pm

IO360° Cancer Immunotherapy Debate

5:35PM - 6:10PM

IO360° Annual Debate

Showing Events in 1 Track from 07:45am to 08:45am

Morning Remarks

7:45AM - 8:15AM

Registration & 1:1 Meetings

8:15AM - 8:20AM

Co-Chairs’ Welcome

8:20AM - 8:45AM

Fireside Keynote: What’s Next in Immuno-Oncology - A Visionary Conversation with Dr. Ira Mellman

Fireside Guest:

Ira Mellman, PhD, President of Research, Parker Institute for Cancer Immunotherapy (PICI)

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Showing Events in 1 Track from 08:45am to 09:25am

State of the IO Market, Investments and Deals Plenary

8:45AM - 9:05AM

IO Capital Markets Outlook for Biotechs & IO

Lorenzo Paoletti, MBA, Managing Director, Biopharma Investment Banking, Bank of America

9:05AM - 9:25AM

M&A Strategies in Biotech: Navigating the Path to Acquisition

Rick Aldridge, MBChB, Managing Director, Healthcare Investment Banking

Showing Events in 1 Track from 09:25am to 10:05am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

9:25AM - 10:05AM

Morning Networking Break

Showing Events in 1 Track from 10:05am to 10:50am

IO360° Biotech Showcase

10:05AM - 10:50AM

IO360° Biotech Showcase

Participating Companies:

Showing Events in 1 Track from 10:50am to 10:55am

5 Minute Health Break

10:50AM - 10:55AM

5 Minute Health Break

Showing Events in 1 Track from 10:55am to 12:15pm

State of the IO Market, Investments and Deals Plenary (Continued)

10:55AM - 11:35AM

What Makes a Smart Deal in IO? Navigating Capital, Competition, and Global Innovation

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Markus Werner, PhD, Head, Search & Evaluation, Oncology, Novartis

Evan Zisholtz, JD, VP, Global Business Development, Immunai

11:35AM - 12:15PM

IO Investment Trends: What’s Driving Capital in 2026?

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Reni Benjamin, PhD, Managing Director, Citizens Capital Markets and Advisory

Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley

Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments

I-hung Shih, PhD, MBA, Managing Director & Portfolio Manager, Eventide Asset Management

Showing Events in 1 Track from 12:15pm to 01:15pm

Lunch

12:15PM - 1:15PM

Lunch & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 01:20pm to 03:20pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers

1:20PM - 1:40PM

VIP Talk: Targeting Myeloid Cells for Therapeutic Enhancement

Engineering the Optimal T Cell Engager: From Molecular Design to Clinical Translation

Julie Bailis, PhD, Associate Vice President, Acting Head of Oncology Research, Amgen

2:40PM - 3:00PM

Synergizing Cell Therapy with Oncolytic Viruses for Enhanced Tumor Targeting

Barbra Sasu, CSO, Dispatch Bio

3:00PM - 3:20PM

First-in-Human Imaging of a Zirconium-89-Labeled Monoclonal Antibody in Small Cell Lung Cancer

Diederik Grootendorst, PhD, Director, Global Oncology Imaging, Bristol Myers Squibb

TRACK 2: IO Cell Therapy Plenary

1:20PM - 1:55PM

In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment

Adrian Bot, MD, PhD, EVP, R&D and Founding CSO, Capstan Therapeutics

Jacek Lubelski, PhD, Chief Technology Officer, NanoCell Therapeutics

1:55PM - 2:15PM

Beyond T Cells: The Rise of Non-Immune Cell Therapies

2:15PM - 2:30PM

Islet Transplantation for Type 1 Diabetes

Autologous iPSC Therapy for Parkinson’s

2:30PM - 2:45PM

2:45PM - 3:20PM

iPSC 2.0: From Promise to Productization

Dhavalkumar Patel, MD, PhD, EVP & CSO, Sana Biotechnology

Gregory Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics

Bahram (Bob) Valamehr, PhD, President & CEO, Fate Therapeutics

Showing Events in 1 Track from 03:20pm to 04:00pm

Afternoon Networking Break

3:20PM - 4:00PM

Afternoon Networking Break & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 04:00pm to 05:30pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers

4:00PM - 5:30PM

Breakthroughs in Translational Science, Imaging & Biomarkers Sessions Coming Soon

TRACK 2: IO Cell Therapy Plenary

4:00PM - 4:35PM

Rebuilding TCR-T Cell Therapy: Novel Targets, Smarter Circuits, and the Road to Universality

Moderator:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting